Apellis Pharmaceuticals (NASDAQ:APLS) Given Neutral Rating at Mizuho

Mizuho reaffirmed their neutral rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS) in a research report report published on Wednesday, Benzinga reports. They currently have a $60.00 price target on the stock.

Other analysts also recently issued research reports about the company. Jefferies Financial Group upgraded Apellis Pharmaceuticals from a hold rating to a buy rating and boosted their target price for the stock from $68.00 to $80.00 in a research report on Monday, February 5th. UBS Group boosted their price objective on Apellis Pharmaceuticals from $87.00 to $89.00 and gave the company a buy rating in a research report on Monday, March 4th. HC Wainwright reiterated a buy rating and issued a $92.00 price objective on shares of Apellis Pharmaceuticals in a research report on Wednesday, February 28th. Wells Fargo & Company downgraded Apellis Pharmaceuticals from an overweight rating to an equal weight rating and dropped their target price for the stock from $67.00 to $54.00 in a report on Thursday, December 14th. Finally, The Goldman Sachs Group boosted their target price on Apellis Pharmaceuticals from $65.00 to $90.00 and gave the stock a buy rating in a report on Tuesday, January 9th. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of Moderate Buy and a consensus price target of $77.93.

Apellis Pharmaceuticals Stock Performance

NASDAQ:APLS opened at $58.49 on Wednesday. The business has a 50 day moving average of $63.56 and a 200 day moving average of $55.81. The company has a market capitalization of $7.05 billion, a price-to-earnings ratio of -13.06 and a beta of 0.90. Apellis Pharmaceuticals has a 1-year low of $19.83 and a 1-year high of $94.75. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.10 and a quick ratio of 2.50.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its earnings results on Tuesday, February 27th. The company reported ($0.73) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.73). The company had revenue of $146.38 million during the quarter, compared to the consensus estimate of $143.34 million. Apellis Pharmaceuticals had a negative return on equity of 178.60% and a negative net margin of 133.34%. Apellis Pharmaceuticals’s quarterly revenue was up 545.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.50) EPS. On average, sell-side analysts predict that Apellis Pharmaceuticals will post -1.36 earnings per share for the current fiscal year.

Insider Activity

In other Apellis Pharmaceuticals news, insider Caroline Baumal sold 2,751 shares of the stock in a transaction dated Thursday, January 4th. The stock was sold at an average price of $60.05, for a total value of $165,197.55. Following the transaction, the insider now owns 32,931 shares of the company’s stock, valued at $1,977,506.55. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Apellis Pharmaceuticals news, CFO Timothy Eugene Sullivan sold 2,235 shares of the stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $66.81, for a total value of $149,320.35. Following the transaction, the chief financial officer now owns 99,226 shares of the company’s stock, valued at $6,629,289.06. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Caroline Baumal sold 2,751 shares of the stock in a transaction dated Thursday, January 4th. The shares were sold at an average price of $60.05, for a total value of $165,197.55. Following the completion of the transaction, the insider now directly owns 32,931 shares in the company, valued at approximately $1,977,506.55. The disclosure for this sale can be found here. Insiders have sold a total of 351,923 shares of company stock valued at $22,361,395 over the last ninety days. 7.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Wynnefield Capital Inc. purchased a new stake in Apellis Pharmaceuticals in the third quarter worth about $380,000. General American Investors Co. Inc. purchased a new stake in Apellis Pharmaceuticals in the third quarter worth about $1,712,000. Profund Advisors LLC increased its position in Apellis Pharmaceuticals by 114.5% in the third quarter. Profund Advisors LLC now owns 35,153 shares of the company’s stock worth $1,337,000 after buying an additional 18,766 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in Apellis Pharmaceuticals by 6.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 879,357 shares of the company’s stock worth $33,451,000 after buying an additional 50,835 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its position in Apellis Pharmaceuticals by 105.2% in the third quarter. Assenagon Asset Management S.A. now owns 1,023,507 shares of the company’s stock worth $38,934,000 after buying an additional 524,797 shares in the last quarter. Institutional investors own 96.29% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).